With the current pathophysiological data, clinical evidence, and recent innovations about the relevant role of GLP-1 RA in preventing HFpEF and its effects on reverse remodeling and clinical outcomes, important mechanistic questions remain in patients with obesity, metabolic syndrome, or in obese type II diabetic patients. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.